Search Within

Weinberg Fellows

Formats
  1. Meeting Abstract (1374)
  2. Journal Article (1150)
  3. Review (130)
  4. Editorial (65)
  5. Research Letter (36)
  6. Book Section (25)
  7. Correspondence (24)
  8. Guidelines (12)
  9. Conference Paper (2)
  10. Miscellaneous (1)
Groups
  1. Hematology-Oncology Fellows (2746)
  2. Department of Medicine (2703)
  3. Solid Tumor Oncology Division (2002)
  4. Hematologic Malignancies, Division of (1330)
  5. GSK Faculty (1228)
  6. Department of Pathology and Laboratory Medicine (982)

More Groups

People
  1. Michael Berger (218)
  2. Marc Ladanyi (198)
  3. Pedram Razavi (184)
  4. Michael Offin (176)
  5. Sergio Giralt (171)
  6. Maria Carlo (168)

More People

Years
  1. 2025 (206)
  2. 2024 (414)
  3. 2023 (330)
  4. 2022 (377)
  5. 2021 (339)
  6. 2020 (323)

More Years

Publications
  1. Journal of Clinical Oncology (568)
  2. Blood (299)
  3. Annals of Oncology (107)
  4. Clinical Cancer Research (102)
  5. Journal of Thoracic Oncology (96)
  6. Cancer Research (87)

More Publications

Publishers
  1. American Society of Clinical Oncology (643)
  2. Elsevier Inc. (343)
  3. American Society of Hematology (339)
  4. American Association for Cancer Research (239)
  5. Nature Publishing Group (201)
  6. Oxford University Press (157)

More Publishers

Results (2819)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Frequency of brain metastases and outcomes in patients with HER2-, KRAS-, and EGFR-mutant lung cancers
    Meeting Abstract

    Kris, M. G.; Offin, M. D.; Feldman, D. L.; Ni, A.; Lai, W. C. V.; Arbour, K. C.; Daras, M.; Pentsova, E.; DeAngelis, L. M.; Beal, K.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • PD-L1 expression, tumor mutation burden and response to immune checkpoint blockade in patients with HER2-mutant lung cancers
    Meeting Abstract

    Lai, W. C. V.; Feldman, D. L.; Buonocore, D. J.; Brzostowski, E. B.; Rizvi, H.; Plodkowski, A. J.; Ni, A.; Sabari, J. K.; Offin, M. D.; Kris, M. G.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A phase II study of talimogene laherparepvec (T-VEC) and pembrolizumab in patients with metastatic sarcoma
    Meeting Abstract

    Kelly, C. M.; Bowler, T. G.; Munhoz, R. R.; Chi, P.; Dickson, M. A.; Gounder, M. M.; Keohan, M. L.; Dholakia, R.; Condy, M. M.; Singer, S.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Pembrolizumab-based therapy in previously treated high grade extrapulmonary neuroendocrine carcinomas
    Meeting Abstract

    Hooker, C.; Chan, J. A.; Aggarwal, R. R.; Cinar, P.; Hope, T.; Kolli, K.; Zhang, L.; Calabrese, S.; Grabowsky, J. A.; Zhang, J.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A multicenter pilot study of nivolumab (NIVO) with drug eluting bead transarterial chemoembolization (deb-TACE) in patients (pts) with liver limited hepatocellular carcinoma (HCC)
    Meeting Abstract

    Harding, J. J.; Erinjeri, J. P.; Tan, B. R.; Reiss, K. A.; Mody, K.; Khalil, D.; Yarmohammadi, H.; Nadolski, G.; Giardina, J. D.; Capanu, M.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Multigene sequencing, copy number alteration detection, and survival with first-line PD-1 based therapy in patients with mucosal melanoma
    Meeting Abstract

    Gottesdiener, L. S.; Gormally, M.; Armenia, J.; El-Jalby, M.; Postow, M. A.; Callahan, M. K.; Momtaz, P.; Wolchok, J. D.; Chapman, P. B.; Schultz, N.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Single-center analysis of 109 patients (pts) with metastatic chromophobe renal cell carcinoma (ChRCC): Differences in outcomes by histologic variant
    Meeting Abstract

    Ged, Y.; Knezevic, A.; Chen, Y.; Redzematovic, A.; Carlo, M. I.; Lee, C. H.; Feldman, D. R.; Patil, S.; Motzer, R. J.; Voss, M. H.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Etoposide and cisplatin (EP) for metastatic good-risk germ cell tumors (GCTs): The Memorial Sloan-Kettering Cancer Center (MSKCC) experience in 944 patients (pts)
    Meeting Abstract

    Funt, S.; McHugh, D. J.; Tsai, S.; O'Donnell, D.; Knezevic, A.; Patil, S.; Silber, D.; Reuter, V. E.; Sheinfeld, J.; Carver, B. S.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • The clinical utility of prospective molecular characterization in advanced cervical and vulvovaginal cancer
    Meeting Abstract

    Friedman, C. F.; Donoghue, M.; Vivek, M.; Aghajanian, C.; Abu-Rustum, N.; Cadoo, K. A.; Grisham, R. N.; Hensley, M. L.; Konner, J. A.; Kyi, C.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Multicenter randomized phase 2 trial of paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for first-line treatment of patients (pts) with intermediate- or poor-risk germ cell tumors (GCT)
    Meeting Abstract

    Feldman, D. R.; Hu, J.; Srinivas, S.; Stadler, W. M.; Costello, B. A.; Appleman, L. J.; Milowsky, M. I.; Patil, S.; Bromberg, M.; Nolan, P.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save